TY - JOUR T1 - Diagnosing pediatric mitochondrial disease: lessons from 2,000 exomes JF - medRxiv DO - 10.1101/2021.06.21.21259171 SP - 2021.06.21.21259171 AU - Sarah L. Stenton AU - Masaru Shimura AU - Dorota Piekutowska-Abramczuk AU - Peter Freisinger AU - Felix Distelmaier AU - Johannes A. Mayr AU - Christine Makowski AU - Boriana Büchner AU - Bader Alhaddad AU - Charlotte L. Alston AU - Anna Ardissone AU - Rui Ban AU - Ivo Barić AU - Riccardo Berutti AU - Theresa Brunet AU - Elżbieta Ciara AU - Dasha Deen AU - Julien Gagneur AU - Daniele Ghezzi AU - Mirjana Gusic AU - Tobias B. Haack AU - Maja Hempel AU - Ralf A. Husain AU - Daniela Karall AU - Stefan Kölker AU - Urania Kotzaeridou AU - Thomas Klopstock AU - Robert Kopajtich AU - Vassiliki Konstantopoulou AU - Steffen Liez AU - Dominic Lenz AU - Albert Z. Lim AU - Hanna Mandel AU - Robert McFarland AU - Wolfgang Müller-Felber AU - Gerard Muñoz-Pujol AU - Akira Ohtake AU - Yasushi Okazaki AU - Rikke Olsen AU - Ewa Pronicka AU - Angela Pyle AU - Antonia Ribes AU - Dariusz Rokicki AU - René Santer AU - Manuel Schiff AU - Markus Schuelke AU - Dmitrii Smirnov AU - Wolfgang Sperl AU - Tim Strom AU - Frederic Tort AU - Polina Tsygankova AU - Rudy van Coster AU - Patrick Verloo AU - Jürgen-Christoph von Kleist-Retzow AU - Ekkehard Wilichowski AU - Tekla Wolstein AU - Manting Xu AU - Vicente Yépez AU - Michael Zech AU - Saskia Wortmann AU - Matias Wagner AU - Costanza Lamperti AU - Robert W. Taylor AU - Fang Fang AU - Agnés Rötig AU - Kei Murayama AU - Thomas Meitinger AU - Holger Prokisch Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/25/2021.06.21.21259171.abstract N2 - Background The spectrum of mitochondrial disease is genetically and phenotypically diverse, resulting from pathogenic variants in over 400 genes, with aerobic energy metabolism defects as a common denominator. Such heterogeneity poses a significant challenge in making an accurate diagnosis, critical for precision medicine.Methods In an international collaboration initiated by the European Network for Mitochondrial Diseases (GENOMIT) we recruited 2,023 pediatric patients at 11 specialist referral centers between October 2010 and January 2021, accumulating exome sequencing and HPO-encoded phenotype data. An exome-wide search for variants in known and potential novel disease genes, complemented by functional studies, followed ACMG guidelines.Results 1,109 cases (55%) received a molecular diagnosis, of which one fifth have potential disease-modifying treatments (236/1,109, 21%). Functional studies enabled diagnostic uplift from 36% to 55% and discovery of 62 novel disease genes. Pathogenic variants were identified within genes encoding mitochondrial proteins or RNAs in 801 cases (72%), while, given extensive phenotype overlap, the remainder involved proteins targeted to other cellular compartments. To delineate genotype-phenotype associations, our data was complemented with registry and literature data to develop “GENOMITexplorer”, an open access resource detailing patient- (n=3,940), gene- (n=427), and variant-level (n=1,492) associations (prokischlab.github.io/GENOMITexplorer/).Conclusions Reaching a molecular diagnosis was essential for implementation of precision medicine and clinical trial eligibility, underlining the need for genome-wide screening given inability to accurately define mitochondrial diseases clinically. Key to diagnostic success were functional studies, encouraging early acquisition of patient- derived tissues and routine integration of high-throughput functional data to improve patient care by uplifting diagnostic rate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge support by the German Federal Ministry of Education and Research (BMBF, Bonn, Germany) awarded grant to the German Network for Mitochondrial Disorders (mitoNET, 01GM1906A), the German BMBF and Horizon2020 through the E-Rare project GENOMIT (01GM1920A, genomit.eu), and the ERA PerMed project PerMiM (01KU2016A, permim.eu). AR and MS acknowledge the Association Francais contre les Myopathies, GIS-Institut des Maladies Rares, French Agence Nationale pour la Recherche (A.N.R.), Association contre les Maladies Mitochondriales (AMMi), Fondation Maladies Rares, Collaboration CEA/IG/CNG-INSERM, MSD-Avenir for Devo-Decode project, and Bioresources of the Necker Imagine DNA biobank (BB-033-00065). RM and RWT are supported by the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Lily Foundation and the UK NHS Specialised Commissioners who fund the Rare Mitochondrial Disorders of Adults and Children Service in Newcastle upon Tyne. CLA is supported by an NIHR postdoctoral fellowship (PDF-2018-11-ST2-02). AR, GMP, and FT were supported by the Instituto de Salud Carlos III (PI16/01048; PI19/01310) (Co-funded by European Regional Development Fund A way to make Europe) and the Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), an initiative of the Instituto de Salud Carlos III (Ministerio de Ciencia e Innovacion, Spain), the Departament de Salut, Generalitat de Catalunya (URDCAT project, SLT002/16/00174), the Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) (2017: SGR 1428) and the CERCA Programme/Generalitat de Catalunya. TK is a member of the European Reference Network for Rare Neurological Diseases (ERN-RND-Project ID No 739510). TBH was supported by the German Bundesministerium fur Bildung und Forschung (BMBF) through the Juniorverbund in der Systemmedizin mitOmics (FKZ 01ZX1405). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethikkommission Technische Universitat Munchen. Ethikkommission Ludwig-Maximilians-Universitat Munchen. Ethikkommission Bundesland Salzburg. Comitato Etico Regione Lombardia Sezione Fondazione IRCCS Istituto Neurologico "Carlo Besta". NRES Committee North East. Chiba University. Institut Imagine. Capital Medical University. Institutional Ethics Committee of the Federal State Budgetary Institution "Research Centre for Medical genetics". Commissie voor medische ethiek UZ-Gent. Ethics Committee of The Childrens Memorial Health Institute. "Comite de Etica de la Investigacion" del Hospital Clinic de Barcelona.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed for the analysis presented in the manuscript are available on GENOMITexplorer (https://prokischlab.github.io/GENOMITexplorer/). https://prokischlab.github.io/GENOMITexplorer/ ER -